Hospital General Universitario De Valencia
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Hospital General Universitario De Valencia is investigating novel anticoagulation strategies for atrial fibrillation, aiming to lower the risk of stroke and systemic embolism through a direct comparison of new agents with established therapy.
- Atrial fibrillation management
- Prevention of cardioembolic events
- Evaluation of alternative anticoagulants
- Stroke risk reduction outcomes
Across its portfolio of 13 trials, the site engages 72 investigators, integrating cardiovascular research within its broader clinical program.
Hormonal diseases
The department conducts endocrine studies focused on chronic hypoparathyroidism, testing a recombinant peptide to enhance calcium homeostasis and improve patient well‑being.
- Chronic hypoparathyroidism treatment
- Calcium and vitamin D regulation
- Hormone replacement strategies
- Bone health and metabolic balance
These investigations complement the hospital’s efforts in metabolic health and support a multidisciplinary approach to hormonal disorders.
Immune System Diseases
Researchers are evaluating targeted biologics such as rocatinlimab in combination with topical therapies for moderate‑to‑severe atopic dermatitis, seeking faster skin clearance and sustained disease control.
- Atopic dermatitis biologic therapy
- Combination with corticosteroids or calcineurin inhibitors
- Eczema Area and Severity Index improvement
- Immune pathway modulation
This work leverages the site’s expertise in immune modulation, aligning with its oncology immunotherapy programs.
Neoplasms
A core research focus is on advanced solid tumors, where innovative immunotherapies including nivolumab, relatlimab, and botensilimab are studied to extend progression‑free survival and improve response rates in melanoma, colorectal, and ovarian cancers.
- Advanced melanoma (treated and refractory)
- Metastatic colorectal cancer with dMMR
- Advanced epithelial ovarian cancer
- Unresectable melanoma treatment
- Adjuvant therapy for resected melanoma
The oncology unit leads 13 active trials, reflecting a strong commitment to advancing cancer care.
Nutritional and Metabolic Diseases
Clinical studies target obesity and related metabolic conditions, evaluating a multi‑agonist peptide retatrutide for weight reduction and exploring its potential benefits for knee osteoarthritis.
- Obesity and overweight management
- Knee osteoarthritis symptom relief
- Metabolic syndrome intervention
- Weight‑loss efficacy assessment
By integrating metabolic research with oncology, the site offers patients access to cutting‑edge therapeutic options.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 24 therapeutic areas and 15 of 360 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 338 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 71 by active trials.
- 1Merck Sharp & Dohme LLC7active
lock +70 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC13trials
lock +35 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital General Universitario De Valencia
lock Showing 1 of 225 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 360 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 31 | Unknown | 2018-08-24 | 2026-06-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.